Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.63 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.55 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.55 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427143 | 1.00 | ENPP2 (0.63) | ENPP2ORAI1ORAI2ORAI3TP53 | |
| SCHEMBL29954865 | 0.81 | ENPP2 (0.48) | ENPP2ORAI1ORAI2ORAI3KDM4E | |
| SCHEMBL1771335 | 0.81 | ENPP2 (0.48) | ENPP2ORAI1ORAI2ORAI3KDM4E | |
| SCHEMBL3790244 | 0.79 | CA1 (0.58) | ENPP2TP53KDM4EALDH1A1LMNA | |
| SCHEMBL14120757 | 0.79 | ENPP2 (0.46) | ENPP2ORAI1ORAI2ORAI3ALDH1A1 | |
| SCHEMBL29951150 | 0.79 | ENPP2 (0.46) | ENPP2ORAI1ORAI2ORAI3ALDH1A1 | |
| SCHEMBL23807 | 0.78 | ENPP2 (1.00) | ENPP2ORAI1ORAI2ORAI3TP53 | |
| SCHEMBL29466484 | 0.78 | ENPP2 (1.00) | ENPP2ORAI1ORAI2ORAI3TP53 | |
| SCHEMBL2446918 | 0.77 | ENPP2 (0.41) | ENPP2ORAI1ORAI2ORAI3ALDH1A1 | |
| SCHEMBL29955371 | 0.77 | ENPP2 (0.41) | ENPP2ORAI1ORAI2ORAI3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12610732-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-12497420-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4358685-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4650415-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12466813-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250296938-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12391705-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2025-08-14 | — | — | US | disclosed |
| EP-4155293-B1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2025-02-25 | — | — | US | disclosed |
| EP-2663550-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VentiRx Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2012097173-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | ENPP2 678/4885ORAI1 1111/4885ORAI2 2717/4885 |
| US-12466813-B2 | PRC1 inhibitors and methods of treatment therewith | BMI1, EZH2, CBX3 | ENPP2 2770/4885ORAI1 4851/4885ORAI2 4741/4885 |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM2 | ENPP2 678/4885ORAI1 1111/4885ORAI2 2717/4885 |
| US-12610732-B2 | Organic electroluminescent materials and devices | ICOSLG, SSB, SART3 | ENPP2 1952/4885ORAI1 2084/4885ORAI2 1675/4885 |
| US-12497420-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, OR10J3 | ENPP2 1397/4885ORAI1 426/4885ORAI2 145/4885 |
| US-12391705-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | ENPP2 337/4885ORAI1 4083/4885ORAI2 4144/4885 |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | ENPP2 1139/4885ORAI1 1835/4885ORAI2 2143/4885 |
| US-20250296938-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | ENPP2 337/4885ORAI1 4083/4885ORAI2 4144/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | ENPP2 388/4885ORAI1 4628/4885ORAI2 3155/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | ENPP2 557/4885ORAI1 3022/4885ORAI2 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.